BCL10 and ovarian carcinoma: MiR-106a and miR-591 have important roles in conferring paclitaxel resistance to ovarian cancer cells, and modulating miRNAs to resensitize paclitaxel-resistant cancer cells by regulating BCL10, caspase-7, and ZEB1 [21].